Clinical Studies Will Be Featured in HEALING Symposium and Scientific Sessions; Data Support the Use of Genous Stent in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable

HONG KONG, OrbusNeich today announced that data from multiple studies of the Genous Stent will be presented at EuroPCR 2011 in Paris. Clinical studies supporting the use of the Genous Stent and its endothelial progenitor cell (EPC) capture technology in cases where prolonged dual antiplatelet therapy is not advisable will be presented during the HEALING Symposium and in the scientific sessions.

HEALING Symposium

The HEALING Symposium, also titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy," will take place at noon CET on Thursday, May 19, in Room Maillot.  Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and Sigmund Silber, M.D., Ph.D., of Kardiologische Klinik Dr Müller, Munich, will chair the event. The symposium will focus on situations where patients are contraindicated for dual antiplatelet therapy, and consequently drug eluting stents, and the potential for pro-healing stent technology to address these challenging cases.

• Eric Duckers, M.D., Ph.D., of Erasmus University Medical Center in The Netherlands will present data about the mechanism of action and potential benefits of EPC capture technology in an ex vivo arteriovenous (AV) shunt model of human circulating blood. 
• Jonathan Hill, M.D., of King's College in London will provide an overview of those cases in which patients are not ideal candidates for prolonged dual antiplatelet therapy and for which there are potential treatment alternatives.
• Stephen Wai-Luen Lee, M.D., of Queen Mary Hospital in Hong Kong will speak about imaging tools and techniques that can be used to assess arterial healing in patients following percutaneous coronary intervention.
• Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam, will discuss potential requirements for an optimal stent platform in the future.

Scientific Sessions 

Dr. Duckers will also present data along with Renu Virmani, M.D., of the CVPath Institute Inc., in Gaithersburg, Md., during the scientific sessions.  They will each present clinical data demonstrating that the Genous stent accelerates re-endothelialization and reduces thrombogenicity compared to bare metal stents (BMS) through the capture of circulating EPCs.  The presentations are part of an innovation session titled "New stents: pre-clinical studies" taking place at 3 p.m. CET on Wednesday, May 18, in Room 253. 

R. Ahmed, M.D., of the EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy, will present data evaluating the safety of very short-term dual antiplatelet therapy after Genous stent implantation as part of a clinical session titled "Is stent thrombosis still an issue?" taking place at 11 a.m. CET on Friday, May 20, in Room 253.

Source: OrbusNeich